Alicia Castañeda Heredia
Investigador
Research group
Professional network profiles
Last Publications
- Carceller, F, Bautista, F, Van Tinteren, H, Castañeda-Heredia A, Surun, A, Wasti, A, Revon-Rivière, G, Bergamaschi, L, Cortés, M, Hladun-Alvaro, R, Jiménez, I, Giraudi, C, Millen, G, Campbell-Hewson, Q, Juan-Ribelles, A, Van der Lugt, J, Amoroso, L, Bertorello, N, Hargrave, D, Vega-Piris, L, Fagioli, F, Haupt, R, Zwaan, CM, Cañete, A, Morlandj, B, Cerauloi, A, Casanova, M, Verschuur, A, André, N, Aerts, I, Doz, F, Pearson, ADJ, Marshall, LV, Vassal, G, Kearnsj, P, Geoerger, B and Moreno, L Prognostic factors of early mortality in children and adolescents with relapsed/refractory solid tumors participating in dose-finding trials in the targeted and immune therapies era: An ITCC study EUROPEAN JOURNAL OF CANCER . 227: .
- Sentís I, Melero JL, Cebrià A, Grzelak M, Soto M, Michel A, Rovira Q, Rodriguez-Hernandez CJ, Caratù G, Urpi A, Sauvage C, Mendizabal-Sasieta A, Maspero D, Lavarino C, Pascual-Reguant A, Castañeda-Heredia A, Muñoz Perez JP, Mora J, Harari A, Nieto JC, Avgustinova A and Heyn H Spatiotemporal T-cell tracking for personalized T-cell receptor T-cell therapy designs in childhood cancer ANNALS OF ONCOLOGY . 36(9): 1096-1106.
- Cristina Larrosa Espinosa, Mico S, Ramos M, Pérez-Jaume S, Sánchez M, Castañeda-Heredia A, Garraus-Oneca M and Mora J Radiation recall reaction induced by gemcitabine/docetaxel in children: A retrospective study on risk factors and outcomes PEDIATRIC BLOOD & CANCER . 71(10): .
Projects
- Project name:
- Disrupción de enhancers: la nueva generación de terapia epigenética en el sarcoma de Ewing
- Leader
- Jaume Mora Graupera, Sara Sánchez Molina
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- PI24/00804
- Starting - finishing date:
- 2025 - 2027
- Project name:
- ICF (Exploratory study on the provision of care for Adolescent and Young Adult (AYA) cancer patients in the Union)
- Leader
- Andrés Morales La Madrid
- Funding entities:
- European Commission
- Code
- 330301961
- Starting - finishing date:
- 2025 - 2026
- Project name:
- SEHOP-PENCIL study - Personalised mEdiciNe for Cancer in chILdren in Spain
- Leader
- Cinzia Emilia Lavarino
- Funding entities:
- Lavarino, Cinzia Emilia, Instituto de Salud Carlos III (ISCIII), Fundació Privada per a la Recerca i la Docència Sant Joan de Déu - FSJD
- Code
- PMP21/00075
- Starting - finishing date:
- 2022 - 2026
News
-
Survival rate of high-risk neuroblastoma patients treated with next-generation immunotherapy at SJD Barcelona Children's Hospital
Researchers of SJD Barcelona Children's Hospital and of Institut de Recerca Sant Joan de Déu (IRSJD) have published the results of treatment with the humanised anti-GD2 antibody Naxitamab (DanyelzaR) combined with granulocyte-macrophage colony-stimulating factor (GM-CSF; LeukineR) in high-risk neuroblastoma patients.
